TAVR: The Need for a Pacemaker Is Associated with Mortality

Courtesy of Dr. Carlos Fava.

 

TAVR: The Need for a Pacemaker

After a transcatheter aortic valve replacement (TAVR), the incidence of permanent pacemaker (PPM) implantation ranges from 6% to 30% in different studies, depending on the valve type used. This is due to trauma, ischemia, haemorrhage, and atrioventricular node and infranodal tissue oedema, provoking ventricular dyssynchrony similar to that caused by complete left bundle branch block. The evolution of patients requiring permanent pacemaker after TAVR has not been fully studied.

 

This study included 9785 patients from 229 hospitals; 651 (6.65%) of these subjects received a permanent pacemaker.

 

Patients receiving a permanent pacemaker were more frequently men with a higher STS predicted risk of mortality score (7.3% vs. 6.7%; p = 0.004), who received aortic valvuloplasty less often and presented more conduction defects in the baseline echocardiogram.

 

During the procedure, patients requiring a permanent pacemaker received larger valves, with higher oversizing. Mean time between valve replacement and permanent pacemaker implantation was three days.

 

Self-expanding valves (CoreValve) required the implantation of permanent pacemakers more frequently than balloon-expandable valves (E. Sapiens). Extreme-risk or inoperable patients required a permanent pacemaker more frequently than high-risk patients. Hospital stays were longer for patients requiring a PPM.

 

At a year, the need for a permanent pacemaker was associated with an increase in mortality (24.1% vs. 19.6%; hazard ratio [HR]: 1.31; 95% confidence interval [CI]: 1.09 to 1.58) and an increase in a composite of mortality and heart failure (37.3% vs. 28.5%; HR: 1.33; 95% CI: 1.13 to 1.56).

 

The following were predictors of the need for permanent pacemaker implantation after TAVR at 30 days:

  • age;
  • prior conduction defect;
  • aortic valve area ≤0.75 cm2;
  • use of self-expanding valves.

 

Conclusion

The need for a pacemaker is a common complication following TAVR, and it is associated with higher mortality and hospitalization due to heart failure at one year.

 

Editorial

Prior studies argued that permanent pacemaker implantation did not affect outcomes. This study, however, proves the opposite: it is associated to a hard event, mortality, and a higher need for hospitalization due to heart failure. This also increases healthcare costs.

 

The upcoming challenge lies in the development of devices that lower the need for a permanent pacemaker while maintaining or improving current performance.

 

Courtesy of Dr. Carlos Fava. Buenos Aires Favaloro Foundation, Argentina.

 

Original title: Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement. Analysis from the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry.

Reference: Opeyemi O. FadaHunsi, et al. J Am Coll Cardiol Intv 2016;9:2189-99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...